GSK3882347 / GSK - LARVOL DELTA

Preclinical Development of GSK3882347- An Orally Bioavailable, FimH Antagonist for Uncomplicated Urinary Tract Infections (IDWeek 2026) - No abstract available

Preclinical • Infectious Disease

Discovery of GSK3882347, an orally bioavailable, FimH antagonist for uncomplicated urinary tract infections (ACS-Fall 2026) - "This effort led to the discovery of our clinical candidate, GSK3882347, an orally bioavailable, small-molecule, mannoside-based FimH antagonist, which displays low nanomolar potency in inhibiting bacterial binding in a whole cell-based assay, excellent oral bioavailability in rodents, and is efficacious both in preventing and treating bladder infection in uUTI mouse models. If successful in clinical trials, GSK3882347 has the potential to drive transformational change in the antimicrobial resistance space and address significant unmet needs in the management of uUTIs."

Infectious Disease • Nephrology

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections (clinicaltrials.gov) - P1 | N=140 | Completed | Sponsor: GlaxoSmithKline | Recruiting ➔ Completed

Trial completion • Infectious Disease • Nephrology

Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years (clinicaltrials.gov) - P1 | N=27 | Completed | Sponsor: GlaxoSmithKline | Recruiting ➔ Completed

Trial completion • Infectious Disease • Nephrology

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections (clinicaltrials.gov) - P1 | N=122 | Recruiting | Sponsor: GlaxoSmithKline | Suspended ➔ Recruiting | Phase classification: P1b ➔ P1 | N=80 ➔ 122 | Trial completion date: Jul 2024 ➔ Feb 2025 | Trial primary completion date: Jul 2024 ➔ Jan 2025

Enrollment change • Enrollment open • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Nephrology

Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: GlaxoSmithKline | Suspended ➔ Recruiting | Trial completion date: Aug 2023 ➔ Oct 2024 | Trial primary completion date: Aug 2023 ➔ Sep 2024

Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease • Nephrology

C-mannoside FimH antagonists as oral therapeutics for urinary tract infections (ACS-Sp 2024) - "In mouse models of UTI, lead compounds showed robust efficacy at reducing bacterial burdens when dosed as low as 0.5 mg/kg. These efforts have led to the identification and selection of clinical candidate, GSK3882347, currently being evaluated in Phase 1b clinical trials as a novel, antibiotic-sparing treatment for acute UTI."

Infectious Disease • Nephrology

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections (clinicaltrials.gov) - P1b | N=80 | Suspended | Sponsor: GlaxoSmithKline | Trial completion date: Dec 2023 ➔ Jul 2024 | Trial primary completion date: Dec 2023 ➔ Jul 2024

Trial completion date • Trial primary completion date • Infectious Disease • Nephrology

Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years (clinicaltrials.gov) - P1 | N=30 | Suspended | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Suspended

Trial suspension • Infectious Disease • Nephrology

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections (clinicaltrials.gov) - P1b | N=80 | Suspended | Sponsor: GlaxoSmithKline | Recruiting ➔ Suspended

Trial suspension • Infectious Disease • Nephrology

Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1 trial • Infectious Disease • Nephrology

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections (clinicaltrials.gov) - P1b | N=80 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Jun 2023 ➔ Dec 2023 | Trial primary completion date: Jun 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date • Infectious Disease • Nephrology

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections (clinicaltrials.gov) - P1b | N=80 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Nephrology

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections (clinicaltrials.gov) - P1b | N=80 | Not yet recruiting | Sponsor: GlaxoSmithKline | Initiation date: Dec 2021 ➔ Mar 2022

Trial initiation date • Infectious Disease • Nephrology

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections (clinicaltrials.gov) - P1b; N=80; Not yet recruiting; Sponsor: GlaxoSmithKline

Clinical • New P1 trial • Infectious Disease • Nephrology

Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants. (clinicaltrials.gov) - P1; N=61; Completed; Sponsor: GlaxoSmithKline; Recruiting ➔ Completed

Trial completion • Infectious Disease • Nephrology